Belgium· BE-AMP-SAM661428-00
Xenpozyme 4 mg
A olipudase alfa product containing olipudase alfa, registered in Belgium by Sanofi. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Olipudase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB25 (olipudase alfa), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Olipudase alfa · ATC A16AB25
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Olipudase Alfa
- Manufacturer
- Sanofi
- Country
- Belgium (BE)
- ATC code
- A16AB25
- ATC class
- Olipudase alfa
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4710208
- be_apb7740509
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Olipudase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXENPOZYMESanofi B.V., Amsterdam
- SwitzerlandXenpozyme 4 mg, poudre pour solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- SpainXENPOZYME 4 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSanofi B.V.
- FinlandXenpozymeSanofi B.V.
- PolandXenpozymeSanofi B.V.
- SwedenXenpozyme 4 mg Pulver till koncentrat till infusionsvätska, lösningSanofi B.V.
- United StatesXENPOZYMEGenzyme Corporation
- NetherlandsXenpozyme 20 mg, poeder voor concentraat voor oplossing voor infusieGenzyme Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xenpozyme
- Liechtenstein · Xenpozyme
- Norway · Xenpozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da944fd2-e35c-4061-a794-384ec5cc9326 GET /v1/drugs/da944fd2-e35c-4061-a794-384ec5cc9326?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Xenpozyme 4 mg",
"name_fr": "Xenpozyme 4 mg",
"name_nl": "Xenpozyme 4 mg",
"amp_code": "SAM661428-00",
"strengths": [
"4.0000",
"4.0000",
"0.6000"
],
"pack_count": 3,
"substances": [
"Olipudase Alfa",
"Sucrose",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Olipudase Alfa",
"authorisation_numbers": [
"EU/1/22/1659/007",
"EU/1/22/1659/006",
"EU/1/22/1659/005"
]
}See everything about olipudase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.